HelloBetter

The company's primary business involves creating evidence-based digital therapy programs for a spectrum of mental health conditions, including stress, burnout, panic disorders, insomnia, and chronic pain. HelloBetter's business model is centered on the prescription digital therapeutic (PDTx) market, particularly within Germany's statutory health insurance system. Under Germany's Digital Healthcare Act (DVG), physicians and psychotherapists can prescribe HelloBetter's certified programs, known as DiGA (Digitale Gesundheitsanwendungen). This allows patients to access the online courses at no personal cost, with reimbursement fully covered by all public health insurers. The platform delivers its programs through a combination of interactive content (texts, videos, audios), practical exercises, and an online diary, complemented by support from trained psychologists who provide feedback.

A significant milestone was achieved when six of its programs were officially listed in Germany's DiGA directory by the Federal Institute for Drugs and Medical Devices (BfArM), cementing its position in the national healthcare system. This integration makes its services available to a large portion of the German population. The company is also expanding internationally, entering the US market in 2022 with its HelloGina brand for vaginismus and pursuing market entry in France. In 2023, its digital therapeutic for panic disorders, 'HelloBetter Panic', received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA), a program designed to expedite the review of medical devices that treat debilitating conditions. The company has successfully raised capital, including a Series A round, to fund product development and international expansion.